FDA issues 'emergency use' green light for remdesivir for treatment of severe COVID-19 disease

The temporary authorisation, under set criteria, is for emergency use of remdesivir for the treatment of adults and children hospitalised with severe COVID-19 disease and is based on limited data which showed that remdesivir accelerated recovery time (11 vs 15 days with placebo).

SPS commentary:

The FDA states that this authorisation is temporary and does not take the place of the formal new drug application submission, review and approval process